Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Youngjoo Lee, Hye Ryun Kim, Min Hee Hong, Ki Hyeong Lee, Keon Uk Park, Geon Kook Lee, Hyae Young Kim, Soo-Hyun Lee, Kun Young Lim, Sung Jin Yoon, Byoung Chul Cho, Ji-Youn Han
BACKGROUND: This study evaluated whether an addition of bevacizumab to erlotinib improves clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). METHODS: This is an open-label, multicenter, randomized Phase 2 study in South Korea. Chemonaïve patients with Stage IIIB/IV NSCLC with EGFR 19 deletion or L858R mutation were eligible. Asymptomatic brain metastasis (BM) was enrolled without local treatment. Patients received either erlotinib plus bevacizumab or erlotinib...
November 30, 2022: Cancer
#2
JOURNAL ARTICLE
Prajwal C Boddu, Jayastu Senapati, Farhad Ravandi-Kashani, Elias J Jabbour, Nitin Jain, Mary Ayres, Yuling Chen, Michael J Keating, Hagop M Kantarjian, Varsha Gandhi, Tapan M Kadia
BACKGROUND: Nelarabine is a purine nucleoside analogue prodrug approved for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and lymphoblastic lymphoma (T-LBL). Although effective in R/R T-ALL, significant neurotoxicity is dose-limiting and such neurotoxicity associated with nucleoside analogues can be related to dosing schedule. METHODS: The authors conducted a phase 1 study to evaluate the pharmacokinetics and toxicity of nelarabine administered as a continuous infusion (CI) for 5 days (120 hours), rather than the standard, short-infusion approach...
November 29, 2022: Cancer
#3
JOURNAL ARTICLE
Carmina G Valle, Molly A Diamond, Hillary M Heiling, Allison M Deal, Derek P Hales, Brooke T Nezami, Bernardine M Pinto, Jessica Gokee LaRose, Christine M Rini, Deborah F Tate
BACKGROUND: Physical inactivity is common in young adult cancer survivors (YACS), but evidence regarding effects of physical activity (PA) interventions among YACS is limited. The IMproving Physical Activity after Cancer Treatment (IMPACT) trial evaluated a theory-based mobile PA intervention on total PA minutes/week (primary) and secondary outcomes (moderate-to-vigorous PA [MVPA], light PA, steps, sedentary behaviors) at 6 months in YACS. METHODS: YACS (N = 280) were randomized to an intervention group or self-help group...
November 29, 2022: Cancer
#4
JOURNAL ARTICLE
Isabelle M Dudley, Ceren Sunguc, Emma J Heymer, David L Winter, Jop C Teepen, Fabiën N Belle, Edit Bárdi, Francesca Bagnasco, Thorgerdur Gudmundsdottir, Roderick Skinner, Gisela Michel, Julianne Byrne, Hilde Øfstaas, Momcilo Jankovic, Maja Česen Mazić, Luzius Mader, Jaqueline Loonen, Stanislaw Garwicz, Thomas Wiebe, Daniela Alessi, Rodrigue S Allodji, Nadia Haddy, Desiree Grabow, Peter Kaatsch, Melanie Kaiser, Milena M Maule, Zsuzsanna Jakab, Maria Winther Gunnes, Monica Terenziani, Lorna Zadravec Zaletel, Claudia E Kuehni, Riccardo Haupt, Florent de Vathaire, Leontien C Kremer, Päivi M Lähteenmäki, Jeanette F Winther, Lars Hjorth, Michael M Hawkins, Raoul C Reulen
BACKGROUND: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. METHODS: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries...
November 29, 2022: Cancer
#5
REVIEW
Jude Mary Cénat, Élisabeth Dromer, Wina Paul Darius, Rose Darly Dalexis, Sarah Elizabeth Furyk, Hannah Poisson, Farid Mansoub Bekarkhanechi, Muhammad Shah, David Guangyu Diao, Andi Phaelle Gedeon, Sophie Lebel, Patrick R Labelle
BACKGROUND: In Canada, two of five individuals will be diagnosed with cancer in their lifetime and one in four will die from this disease. Given the disparities observed in health research among Black individuals, we conducted a scoping review to analyze the state of cancer research in Canadian Black communities regarding prevalence, incidence, screening, mortality, and related factors to observe advances and identify gaps and disparities. METHODS: A comprehensive search strategy was developed and executed in December 2021 across 10 databases (e...
November 27, 2022: Cancer
#6
JOURNAL ARTICLE
Yiling Zheng, Ning Huang, Shuwen Kuang, Jing Zhang, Hong Zhao, Jianxiong Wu, Mei Liu, Liming Wang
BACKGROUND: This study attempts to detect the expression of FoxP3, CD68, CD8α, and PD-L1 in the tumor microenvironment (TME) of intrahepatic cholangiocarcinoma (ICC), and analyze the relationship between the corresponding cells and clinicopathological characteristics as well as prognosis of ICC. METHODS: RNA sequencing (RNA-seq) provided the general landscape of the TME in ICC. A total of 99 ICC patients and the corresponding specimens were used for multiplex immunofluorescence and relapse-free survival (RFS) was analyzed...
November 26, 2022: Cancer
#7
LETTER
Andrew M Fang, Luke A Shumaker, Soroush Rais-Bahrami
No abstract text is available yet for this article.
November 25, 2022: Cancer
#8
LETTER
Pier Paolo Avolio, Massimo Lazzeri, Nicolò Maria Buffi, Giovanni Lughezzani
No abstract text is available yet for this article.
November 25, 2022: Cancer
#9
LETTER
Ioannis D Bassukas, Athina Tatsioni
No abstract text is available yet for this article.
November 25, 2022: Cancer
#10
LETTER
Sarah S Jackson, Anil K Chaturvedi
No abstract text is available yet for this article.
November 25, 2022: Cancer
#11
JOURNAL ARTICLE
Miyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Yasuharu Kikuchi, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Takashi Taida, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Masami Shinozaki, Jun Kato, Naoya Kato
BACKGROUND: Although the efficacy of atezolizumab has been demonstrated in randomized controlled trials, its long-term efficacy and association with adverse events in real-world practice are unknown. This study was designed to shed light on these issues. METHODS: In this multicenter retrospective study, data were collected from patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in seven institutions in Japan. The authors focused on the efficacy and adverse events related to vascular endothelial growth factor (VEGF) inhibition...
November 24, 2022: Cancer
#12
EDITORIAL
Sherin J Rouhani, Christine M Bestvina
No abstract text is available yet for this article.
November 24, 2022: Cancer
#13
JOURNAL ARTICLE
Tareq Salous, Nikhil A Shukla, Sandra K Althouse, Susan M Perkins, Muhammad Furqan, Ticiana Leal, Anne M Traynor, Lawrence E Feldman, Nasser H Hanna, Greg A Durm
BACKGROUND: Immunotherapy using a checkpoint inhibitor (CPI) alone or in combination with chemotherapy is the standard of care for treatment-naive patients with advanced non-small cell lung cancer (NSCLC) without driver mutations for which targeted therapies have been approved. It is unknown whether continuing CPI treatment beyond disease progression results in improved outcomes. METHODS: Patients who experienced progressive disease (PD) after a clinical benefit from chemotherapy plus a CPI were enrolled...
November 24, 2022: Cancer
#14
JOURNAL ARTICLE
Sebastian Sanchez-Luege, Wendy Landier, Chen Dai, Lindsey Hageman, Elizabeth S Ross, Nora A Balas, Alysia Bosworth, Hok Sreng Te, Jessica Wu, Liton Francisco, F Lennie Wong, Stephen J Forman, Saro H Armenian, Daniel J Weisdorf, Smita Bhatia
BACKGROUND: Blood or marrow transplantation (BMT) is increasingly offered to older individuals with hematologic malignancies. The high prevalence of chronic health conditions in such individuals necessitates use of multiple medications. Beers Criteria represent a list of potentially inappropriate medications (PIMs) shown to increase the risk of health problems in the elderly. We sought to determine the prevalence and predictors of PIM use in older BMT survivors and identify associations with health problems...
November 22, 2022: Cancer
#15
JOURNAL ARTICLE
Bharat Nandakumar, Francis Baffour, Nadine H Abdallah, Shaji K Kumar, Angela Dispenzieri, Francis K Buadi, David Dingli, Martha Q Lacy, Suzanne R Hayman, Prashant Kapoor, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Eli Muchtar, Rahma Warsame, Taxiarchis V Kourelis, Ronald S Go, Robert A Kyle, Morie A Gertz, S Vincent Rajkumar, Jason Klug, Panagiotis Korfiatis, Wilson I Gonsalves
BACKGROUND: Sarcopenia increases with age and is associated with poor survival outcomes in patients with cancer. By using a deep learning-based segmentation approach, clinical computed tomography (CT) images of the abdomen of patients with newly diagnosed multiple myeloma (NDMM) were reviewed to determine whether the presence of sarcopenia had any prognostic value. METHODS: Sarcopenia was detected by accurate segmentation and measurement of the skeletal muscle components present at the level of the L3 vertebrae...
November 22, 2022: Cancer
#16
JOURNAL ARTICLE
Youwen Zhu, Kun Liu, Kailing Wang, Hong Zhu
BACKGROUND: Antibody-drug conjugates (ADCs) have complex molecular structures and have been tested in numerous clinical trials. Therefore, understanding the mechanisms of their toxicity when applied in medical practice is of high importance. METHODS: In a systematic review and meta-analysis of data gathered from different scientific databases (PubMed, Embase, Cochrane, and Web of Science) between January 1, 2000, and June 7, 2022, the authors applied a random-effects model with logit transformation and evaluated the heterogeneity between studies using I2 statistics...
November 21, 2022: Cancer
#17
JOURNAL ARTICLE
Daniel L Quan, Jordan S Grauer, Pranit R Sunkara, John D Cramer
BACKGROUND: Survival outcomes are generally better for human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) than other forms of head and neck cancer. However, less is known about oncologic outcomes, late adverse events, and gastrostomy tube dependence associated with salvage surgery after the failure of definitive chemoradiation in patients with HPV+ OPSCC. METHODS: A secondary analysis of the Radiation Therapy Oncology Group 1016 randomized trial, which compared radiotherapy plus cetuximab to radiotherapy plus cisplatin in patients with HPV+ OPSCC, was performed...
November 19, 2022: Cancer
#18
JOURNAL ARTICLE
Jionghui Gu, Tong Tong, Dong Xu, Fang Cheng, Chengyu Fang, Chang He, Jing Wang, Baohua Wang, Xin Yang, Kun Wang, Jie Tian, Tian'an Jiang
BACKGROUND: Neoadjuvant chemotherapy (NAC) can downstage tumors and axillary lymph nodes in breast cancer (BC) patients. However, tumors and axillary response to NAC are not parallel and vary among patients. This study aims to explore the feasibility of deep learning radiomics nomogram (DLRN) for independently predicting the status of tumors and lymph node metastasis (LNM) after NAC. METHODS: In total, 484 BC patients who completed NAC from two hospitals (H1: 297 patients in the training cohort and 99 patients in the validation cohort; H2: 88 patients in the test cohort) were retrospectively enrolled...
November 19, 2022: Cancer
#19
JOURNAL ARTICLE
Rory M Shallis, Naval G Daver, Jessica K Altman, Robert P Hasserjian, Hagop M Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H Wei, David A Sallman, Amer M Zeidan
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
November 17, 2022: Cancer
#20
JOURNAL ARTICLE
Joris Mallard, Elyse Hucteau, Roland Schott, Philippe Trensz, Carole Pflumio, Michal Kalish-Weindling, Fabrice Favret, Xavier Pivot, Thomas J Hureau, Allan F Pagano
BACKGROUND: Fatigue is a hallmark of breast cancer and is associated with skeletal muscle deconditioning. If cancer-related fatigue occurs early during chemotherapy (CT), the development of skeletal muscle deconditioning and its effect on exercise capacity remain unclear. The aim of this study was to investigate the evolution of skeletal muscle deconditioning and exercise capacity in patients with early-stage breast cancer during CT. METHODS: Patients with breast cancer had a visit before undergoing CT, at 8 weeks, and at the end of chemotherapy (post-CT)...
November 17, 2022: Cancer
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
